




Splenomegaly in patients receiving regular hemodialysis. E.
Anastassiades, S. Sherriff, M. M. Plaits, and D. Bartolo.
Department of Medicine, Hallamshire Hospital, Sheffield, Eng-
land. The 174 patients who were receiving maintenance hemo-
dialysis at the Sheffield Renal Unit between April 1979 and April
1980 were requested to take part in the study. After the exclusion
of those who had already undergone splenectomy (8 patients)
and those whose renal failure was due to polycystic kidney
disease (11) or aniyloidosis (3), 89 patients gave their consent.
Each was examined clinically by two observers for the presence
of splenomegaly. A radioisotopic spleen scan was then per-
formed to estimate spleen volume, with either colloid or heat-
damaged erythrocytes labeled with Tc-99m. The mean volume
SD of the palpable spleens (17 patients) was 403 119 ml
(range, 207 to 607) and of the nonpalpable spleens (72 patients)
357 113 ml (161 to 633), the difference between the two groups
being insignificant (Student's t test). The mean for the whole
population was 366 115 ml. Twenty-six patients with function-
ing renal transplants of more than a year (and who had previous-
ly been treated with regular hemodialysis) had a mean spleen
volume of 237 98 ml (range, 127 to 504). Eighteen patients with
chronic uremia (serum creatinine greater than 400 i.moles/liter)
who had never received hemodialysis were also studied. Their
mean spleen volume was 180 57 ml (range, 103 to 272). The
difference in spleen volume between the hemodialysed and the
uremic groups was highly significant (P < 0.001). Equally
significant was the difference between the hemodialysed and the
transplanted groups. The difference between the uremic and the
transplanted patients was also significant (P < 0.05). Conclusion.
Almost all patients receiving hemodialysis treatment have en-
larged spleens. This is the result not of uremia itself but of factors
associated with the procedure of hemodialysis,
Indium-labeled platelet scanning after renal transplantation. A.
Fenech, A. Nicholls, A. MacLeod, and F. Smith. Departments
of Medicine and Medical Physics, University of Aberdeen,
Aberdeen, Scotland. Indium Ill is a high-energy radionuclide
that has been used to label a variety of cells. Platelets are
secondarily involved in both cellular and humoral graft rejection.
A study of "'In-labeled autologous platelets might therefore
provide insight into some of the mechanisms of graft rejection
and also prove useful in diagnosis. Thirteen consecutive cadaver
renal allograft recipients underwent platelet labeling with 150 to
200 j.Ci of '"In performed on the 5th to 10th postoperative day,
followed by daily pelvic imaging with a wide-field gamma camera
for 2 to 5 days. Scans were assessed visually to exclude
extrarenal platelet uptake, and an index of platelet uptake by the
graft was obtained from the ra(io of counts over the graft to
counts from a similar area on the opposite side. Of 43 scans
performed, 30 showed a renal platelet index of < 1.5 ("nega-
tive"), and 13 were "positive" (> 1.5). One patient with
classical rejection initially had a negative scan, but three later
scans showed marked platelet accumulation. All cases of acute
tubular necrosis or normally functioning grafts had negative
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scans. A renal platelet index of> 1.5 only occurred in rejection.
Additional information about extrarenal events was obtained in 3
patients: I with deep venous thrombosis and 2 with perinephric
hematomata. These preliminary results are encouraging. So far,
the method appears both sensitive and specific in distinguishing
between rejection and acute tubular necrosis.
Protein, present in normal human serum, that is immunological-
ly cross-reactive with urinary Tamm-Horsfall glycoprotein. K. L.
Lynn, A. A. Goodall, and R. D. Marshall. Department of
Biochemistry, University of Strathclyde, Glasgow, Scotland.
Tamm-Horsfall glycoprotein is produced by, and associated with
the plasma cell membranes of, cells of the ascending limb of the
loop of Henle and of the distal convoluted tubule. It is shed into
the urine in amounts up to about 100 mg/24 hr by an obscure
mechanism. In vitro testing has revealed that there is cell-
mediated immunity to Tamm-Horsfall glycoprotein in many
patients with renal tubular acidosis accompanying autoimmune
liver disease, and there are increased levels of antibodies that
interact with the glycoprotein in a number of patients with acute
pyelonephritis and infection complicating urinary obstruction.
The nature of any stimulating antigen is unknown. Affinity
chromatography was used to isolate protein, which is immuno-
logically cross-reactive with Tamm-Horsfall glycoprotein, from
normal human serum. The affinity material was a complex of
Sepharose 4B and lgG isolated from antiserum raised in rabbits
against human Tamm-Horsfall glycoprotein. With the use of
sodium thiocyanate (3.5 M) as an eluting agent, two proteins,
which migrate differently (on electrophoresis in the presence of
sodium dodecyl sulphate [SDSI) from the urinary glycoprotein,
were isolated. In control experiments urinary Tamm-Horsfall
glycoprotein, which had previously been bound to the affinity
matrix, could not be recovered with this eluting agent, nor was
protein eluted from columns made with Sepharose 4B coupled to
IgG isolated from the serum of rabbits not immunized. The
cross-reacting serum proteins could also be eluted from the
affinity column with the use of 1% SDS, as could Tamm-Horsfall
glycoprotein in appropriate control experiments. If the latter
were mixed with serum and the mixture subjected to affinity
chromatography, both the serum proteins and the Tamm-Hors-
fall glycoprotein were found in the SDS eluate. The serum
proteins show a lower immunoreactivity than does Tamm-
Horsfall glycoprotein with antibody raised against the latter in
rabbits, and have apparent mol wt's of 125,000 and 84,000
daltons. Further characterization of the serum proteins is re-
quired before firm conclusions can be drawn concerning both the
autoantibodies to Tamm-Horsfall glycoprotein found in certain
pathologic states, and the cross-reacting substance present in
liver.
Diffuse interstitial renal tuberculosis: An unrecognized cause of
renal failure. W. J. W. Mallinson, R. W. Fuller, D. A. Levison,
L. R. I. Baker, and W. R. Cattell. Departments of Nepl,rology
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and Histopathology, St. Bartholomew's Hospital, London, Eng-
land. Renal tuberculosis accounts for 1% of patients reaching
renal replacement programs. Renal failure typically results from
massive caseous destruction of the renal parenchyma or upper
tract obstruction by granulation tissue or fibrosis. We describe
three immigrant patients with renal failure due to histologically
proven tuberculous interstitial nephritis. All three patients were
ill with overt extrarenal tuberculosis. In none was excretion
urography suggestive of tuberculous disease nor were tubercle
bacilli found in the urine. In all three cases there was a chronic
interstitial inflammation with microscopic tuberculous granulo-
mata. In two patients acid-fast bacilli were identified in the renal
tissue. There was no histologic evidence of glomerulonephritis.
Appropriate antituberculous medication was given. In the first
patient, whose renal failure was most severe at the time of
presentation (creatinine clearance, 2 to 5 mI/mm), no improve-
ment in renal function occurred. In the second patient renal
function deteriorated but eventually stabilized while on antitu-
berculous treatment. In the third patient there was marked
fluctuation in renal function, which appeared to correlate with
the varying doses of corticosteroid given in addition to his
antituberculous drugs. Healing of the tuberculous lesions with
severe fibrosis was demonstrated in one patient. Renal infection
by Mycobacterium tuberculosis has not previously been report-
ed to cause this particular histologic and clinical syndrome.
Early diagnosis is important as the poor prognosis for renal
function in the untreated patient may well be improved by early
treatment particularly if corticosteroids and antituberculous
medication are combined.
Circulating immune complexes in minimal-change nephrotic
syndrome. P. Naish, J. Davies, J. Barrait, and R. H. R. White.
Medical Research Laboratories, North Staffordshire Medical
Institute, Stoke-on-Trent, and Department of Paediatric Neph-
rology, Children's Hospital, Birmingham, England. A number of
groups have reported raised concentrations of circulating im-
mune complexes (CIC) in minimal-change nephrotic syndrome(MCNS). To examine more closely the significance of these
findings, we have measured CIC in MCNS using the radiolabeled
monoclonal rheumatoid factor binding assay. Fourteen patients,
nine of whom were frequent relapsers, were investigated serially
over periods of between 3 and 18 months. The majority of
episodes of proteinuria occurring during the absence of any
treatment were associated with raised CIC concentrations. Re-
sponse to prednisone was associated with a fall in CIC concen-
tration in the majority of cases. In addition, steroids appeared to
have a nonspecific CIC-lowering effect. This was shown by three
sets of findings: (a) the majority of patients who relapsed during
steroid therapy had normal CIC levels, (h) CIC concentration
frequently rose to abnormal levels in the absence of relapse
following the reduction or cessation of steroids, and (c) 6 weeks
or more after the induction of remission there was a greater
incidence of raised levels of CIC in patients off treatment than in
those on steroids at this time. Indeed, when CIC concentration in
all patients was related to time after remission, a smaller
proportion of raised CIC levels was seen within 6 weeks of
remission than after this time. The results suggest that CIC
cannot be regarded as directly pathogenetic in MCNS. It is
possible, however, that MCNS patients clear CIC poorly, a
dysfunction that may be altered by steroids. How this might
relate to their therapeutic effect in MCNS is unclear.
Long-term impairment of lymphocyte function after cyclophos-
phamide therapy in patients with minimal-change nephropathy in
remission. D. Taube, Z. Brown, andD. G. Williams. Renal Unit,
Guy's Hospital, London, England. Lymphocyte transformation
by concanavalin A and suppressor cell activity were examined in
31 patients with minimal-change nephropathy (MCN) in remis-
sion. In 29 patients the diagnosis of MCN had been made by
histology of a renal biopsy, and 2 had had a multiple-relapsing
steroid-responsive nephrotic syndrome. Twenty-one patients
had received cyclophosphamide in the past. Their average age
was 32.9 years (range, 10 to 73), and the average period of their
current remission was 4.6 years (range, 0.5 to 9). The average
period since their last course of cytlophosphamide was 5.7 years
(range, Ito 12). All these patients had received corticosteroids in
the past. Ten patients had never received cyclophosphamide.
Their average age was 44i years (range, 26 to 59), and the
average period of their current remission was. years (range,
0.5 to 10). Nine of these patients had received corticosteroids in
the past, one patient having remitted spontaneously. All patients
had normal renal function as assessed by plasma creatinine.
None of the patients was taking cyclophosphamide, corticoster-
oids, or any other drug known to alter lymphocyte function:
corticosteroids had been stopped shortly after the patients' last
remission. The lymphocyte response in the 21 patients treated
previously with cyclophosphamide was significantly lower than
normal (P < 0.001) at each of four doses of concanavalin A (2, 4,
6, and 8 i.g/ml), whereas there was no significant reduction in the
10 patients who had not been treated with this drug. Suppressor
cell function was induced in peripheral blood lymphocytes by
incubation with concanavalin A and assessed by observing their
effects on the mitogen-induced transformation of autologous
lymphocytes. Suppressor cell function was impaired in the group
of patients who had previously received cyclophosphamide but
normal in the nontreated group of MCN patients (P < 0.001).
Suppressor cell function was greater in the group of cyclophos-
phamide-treated patients who continued to relapse after their
cyclophosphamide therapy (P <0.02> 0.01) than in the group of
patients who had had no further relapses, both groups having
been followed up for similar periods of time. These results
indicate that cyclophosphamide exerts a long-term effect on
lymphocyte function, that its efficacy in MCN may depend on its
ability to impair suppressor cell function, and that suppressor
cells may play a role in the pathogenesis of MCN. The prolonged
abnormality in lymphocyte function, coupled with the known
risk of malignancy developing in patients given cyclophospha-
mide, emphasizes the need for caution in using this drug in
diseases without a high mortality rate, and militates against its
use as a first choice in the treatment of MCN, as has recently
been suggested.
Polymorphonuclear leukocyte function in uremia. E. N. War-
dIe. The Liver Unit, Kings College Hospital, London, England.
The susceptibility to infection of patients with uremia is well
known: there is a profound depression of cellular immune
responses. Leukocytes taken from patients with acute uremia
and from chronic dialysis patients were studied for their hexose
monophosphate (HMP) shunt activity, iodination capacity (a
measure of bactericidal function), their myeloperoxidase and
esterase activity, and their ability to take up 4C-leucine (consid-
ered to be a measure of their protein synthetic ability). Further
studies were made to try and define which toxins affect leuko-
cyte iodination and myeloperoxidase function. Normal HMP
shunt activity measured by the oxidation of glucose-1)4C was
125 26 nmoles/hr/106 leukocytes, in acute uremia it was 80
14 (N = 4), and in chronic uremia it was 165 17, so that there
was depression in acute uremia and some increase in chronic
dialysis patients. 14C-leucine uptake was depressed in acute
uremia. Myeloperoxidase activity was depressed in acute uremia
but showed an adaptive increase in activity in chronic uremic
leucocytes. Esterase activity was slightly depressed in cells from
uremic patients. Normal stimulation of leukocyte iodination on
phagocytosis of zymosan was 60 13 nmoles/hr/107 cells, but
acutely uremic leukocytes in their own serum showed a de-
pressed value of 42 10. The same uremic serum lowered the
iodination capacity of normal leukocytes to 50 8 nmoles/hr/l07
cells. By applying suspected toxins in buffer to normal leuco-
cytes, we established that urea, creatinine, methylguanidine and
hippurates do not affect leukocyte iodination, but that there is
suppression by modest concentrations of indole-3-acetic acid
and by phenols and phenolic acids. The results can be rational-
ized by reference to current knowledge of the biochemistry of
leukocyte function.
Specificity of glomerular basal lamina changes in hereditary
nephritis. N. Yoshikawa, R. H. R. White, and A. H. Cameron.
The Children's Hospital, Birmingham, England. Characteristic
ultrastructural alterations of the glomerular basal lamina have
been reported in hereditary nephritis. The basal lamina is irregu-
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larly thickened, and the lamina densa shows replication with a
"basket weave" pattern, enclosing electron-lucent lacunae
which frequently contain small dense particles. But there is
controversy regarding the specificity of this lesion in hereditary
nephritis. To determine its specificity, we studied, retrospective-
ly, 366 renal biopsies from 310 children. Out of 27 patients with
hereditary nephritis, 24 showed the characteristic changes of the
basal lamina, and they were widespread in 17. Two patients with
recurrent hematuria but no family history of deafness or hematu-
na showed similar extensive changes and are regarded as new
mutant cases of hereditary nephritis. Similar changes were seen
in 17 of the 281 patients with other conditions but were always
localized to a few capillary loops. We conclude that a widespread
"basket weave" pattern appears to be confined to hereditary
nephritis and is seen in the great majority of such cases.
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